Skip to main content
European Medicines Agency's logo Go to homepage

Main navigation

  • Medicines
    • Find medicine
    • Therapeutic areas: latest updates
    • Download medicine data
    • What we publish on medicines and when
    • Medicines under evaluation
    • National registers
  • Human regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Medical devices
    • Herbal products
  • Veterinary regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    • Overview
    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    • Overview
    • News
    • Events
    • What's new
    • Committee highlights
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    • Overview
    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    • Overview
    • What we do
    • Who we are
    • How we work
    • Fees
    • Support to SMEs
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Glossaries
    • About this website
    • Data protection and privacy
    • Contacts
  1. Home
  2. Medicines
  3. Imfinzi - opinion on variation to marketing authorisation

Imfinzi - opinion on variation to marketing authorisation

Opinion

EMA has issued an opinion on a change to this medicine's authorisation.

durvalumab
Post-authorisationHuman

Opinion

On 12 October 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Imfinzi. The marketing authorisation holder for this medicinal product is AstraZeneca AB.

The CHMP adopted a new indication as follows:

Imfinzi as monotherapy is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).

For information, the full indications for Imfinzi will be as follows1:

Non-Small Cell Lung Cancer (NSCLC)

Imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non‑small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum‑based chemoradiation therapy (see section 5.1).

Imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations.

Small Cell Lung Cancer (SCLC)

Imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (ES‑SCLC).

Biliary Tract Cancer (BTC)

Imfinzi in combination with gemcitabine and cisplatin is indicated for the first‑line treatment of adults with unresectable or metastatic biliary tract cancer (BTC).

Hepatocellular Carcinoma (HCC)

Imfinzi as monotherapy is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).

Imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.


1 New text in bold

CHMP post-authorisation summary of positive opinion for Imfinzi (II-57)

AdoptedReference Number: EMA/272025/2023

English (EN) (159.32 KB - PDF)

First published: 13/10/2023
View

Key facts

Name of medicine
Imfinzi
EMA product number
EMEA/H/C/004771
Active substance
durvalumab
International non-proprietary name (INN) or common name
durvalumab
Therapeutic area (MeSH)
Carcinoma, Non-Small-Cell Lung
Anatomical therapeutical chemical (ATC) code
L01XC28
Marketing authorisation holder
AstraZeneca AB
Date of opinion
12/10/2023
Status
Positive

News on Imfinzi

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 May 2025
23/05/2025
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2025
28/02/2025
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2025
31/01/2025
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024
28/06/2024
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023
13/10/2023
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022
16/12/2022
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2022
11/11/2022
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020
24/07/2020
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018
27/07/2018

More information on Imfinzi

  • Imfinzi
This page was last updated on 13/10/2023

Share this page

Back to top

Product emergency hotline

OUTSIDE WORKING HOURS

About us
What we do
Careers
Committees & working parties
Regulatory network
European experts
Languages
Frequently asked questions
Glossaries
About this website
Cookies
Website data protection notice
Data protection at EMA
Search tips
Access to documents
Contacts
Send a question
EMA Service Desk (system support)
Services and databases

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us
Postal address and deliveries
Business hours and holidays

  • RSS Feed
  • Bluesky
  • YouTube
  • LinkedIn
© 1995 - 2025 European Medicines Agency
European Union agencies network
An agency of the European Union